The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Improved survival associated with ibrutinib compared to chemotherapy in MCL with CNS relapse
Carlo Visco, MD, University of Verona, Verona, Italy, discusses the results of a study which compared the outcomes of patients with mantle cell lymphoma (MCL) and central nervous system (CNS) relapse treated with ibrutinib versus chemoimmunotherapy. Patients treated with ibrutinib demonstrated an improvement in progression-free survival (PFS), and Dr Visco further comments on the importance of developing novel agents for this difficult-to-treat population. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
